IRE1α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma by Feng, Y et al.
Title
IRE1α inhibition by natural compound genipin on tumour
associated macrophages reduces growth of hepatocellular
carcinoma
Author(s) TAN, HY; Wang, N; Tsao, GSW; Che, CM; Yuen, RMF; Feng, Y
Citation Oncotarget, 2016, v. 7 n. 28, p. 43792-43804
Issued Date 2016
URL http://hdl.handle.net/10722/226290
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Oncotarget43792www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 28
IRE1a inhibition by natural compound genipin on tumour 
associated macrophages reduces growth of hepatocellular 
carcinoma
Hor-Yue Tan1, Ning Wang1, Sai-Wah Tsao2, Chi-Ming Che3, Man-Fung Yuen4, Yibin 
Feng1
1School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R, P.R. of China
2School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R, P.R. of China
3State Key Laboratory of Synthetic Chemistry, Chemical Biology Centre, and Department of Chemistry, The University of 
Hong Kong, Hong Kong S.A.R, P. R. China
4Division of Gastroenterology and Hepatology, Queen Mary Hospital and Department of Medicine, Li Ka Shing Faculty of 
Medicine, The University of Hong Kong, Hong Kong S.A.R, P. R. of China
Correspondence to: Yibin Feng, email: yfeng@hku.hk
Keywords: genipin, tumour-associated macrophage, hepatocellular carcinoma, IRE1a, NF-κB
Received: March 22, 2016    Accepted: April 27, 2016    Published: May 30, 2016
ABSTRACT
Accumulating evidences postulated the influential roles of macrophages in 
mediating hepatocellular carcinoma (HCC) initiation and progression. In this study, we 
demonstrate that a small molecule, genipin reduced HCC growth through suppressing 
IRE1a-mediated infiltration and priming of tumour associated macrophages (TAMs). 
Oral administration of genipin (30mg/kg/2days) suppressed orthotopic HCC tumour 
growth without challenging the viability and proliferation of HCC cells. Genipin reduced 
infiltration of inflammatory monocytes into liver and tumour thereby suppressed TAMs 
presence in HCC microenvironment. Suppression of HCC growth was diminished in 
HCC-implanted mice with depletion of TAMs by liposome clodronate. Genipin inhibited 
the TAMs migration, and reduced expression of TAMs-derived inflammatory cytokines 
that favors HCC proliferation. This is revealed by the in vivo deletion of IRE1a on TAMs 
in genipin-treated HCC-implanted mice. Diminishing IRE1a neutralised the inhibitory 
effect of genipin on TAMs. Silencing the expression of IRE1a greatly reduced TAMs 
migration and expression of inflammatory cytokines that prime HCC proliferation. 
Suppression of IRE1a led to reduced XBP-1 splicing and NF-κB activation. The reduced 
association of IRE1a with TRAF2 and IKK complex may be responsible for the genipin-
mediated inactivation of NF-κB. The findings show the important role of TAMs in 
inhibitory effect of genipin on HCC, and TAMs-expressing IRE1a as a promising target 
for disrupting the tumour environment that favor of HCC development.
INTRODUCTION
To date, the mechanism underlying multistep 
hepatocellular carcinoma (HCC) progression remains 
ambiguous, but studies showed that inflammation may 
be one of the leading factors [1, 2]. Chronic inflammation 
re-programmes the intrahepatic environment to various 
tumorigenesis-promoting niches that favor cancer 
progenitor cell growth [3]. Recent findings proposed that 
the inflammatory response triggered by intestinal microbiota 
resulted in increased proliferation and inactivation of 
apoptotic signalling that promotes HCC progression 
[4]. Inflammation mediated HCC progression is mainly 
attributed by infiltration of inflammatory leukocytes 
into tumour microenvironment [5], and in particular, 
macrophages is regarded as the predominant facilitator in 
HCC tumour progression. Evidences showed that high 
population of macrophages augments HCC invasiveness, 
leading to poor prognosis in HCC patients [6]. The number 
of EGFR-expressing macrophages in HCC is correlated 
with HCC aggressiveness, while the high number of total 
macrophages is associated with low overall survival and 
disease free survival rate in Chinese populations [7]. These 
macrophages are therefore termed as tumour associated 
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macrophages (TAMs) in some previous studies. Indeed, 
targeting of TAMs mediating inflammation may be 
potentially promising for HCC management.
Genipin is an aglycone derived from geniposide, the 
iridoid glycoside mainly found in the fruit of Gardenia 
jasminoides Ellis. Previous studies have postulated the 
potential use of genipin for treatment of osteoporosis, 
diabetic nephropathy, sepsis, and depression [8–11]. 
The anti-tumour effect of genipin is rather scanty, with 
a few reports on its in vitro cytotoxic effect in cervical 
and breast cancer cells [12, 13]. Our previous study has 
showed the inhibitory effect of genipin on intrahepatic 
and distant metastasis of HCC [14]. Interestingly, genipin 
is a well- studied anti-inflammatory metabolite [15] and 
many of its pharmacological activities was rooted from its 
anti-inflammatory action. Genipin inhibited the NLRP3 
and NLRC4 inflammasome resulted in attenuation of in 
vivo peritonitis and lung inflammation in mice [16]. The 
suppressive effect of genipin on vascular smooth muscle 
cell proliferation and migration also correlated to its anti-
inflammatory function [17]. But how the anti-inflammatory 
property of genipin contributes to its anti-tumour effect 
and whether TAMs is involved remains unclear.
In the present study, we investigated any inhibitory 
effect of genipin on orthotopic HCC implantation murine 
model. Simultaneously, TAMs were particularly removed 
with liposome clodronate injection, in order to explore the 
role of TAMs on tumour inhibitory effect of genipin. Bone 
marrow-derived macrophages were differentiated with 
tumour derived supernatant (TSN) to establish the in vitro 
model and the effect of genipin on viability, polarisation 
and priming of macrophages were studied. The involvement 
of IRE1α depletion in mediating inhibition of TAMs 
by genipin and the possible mechanisms were further 
elaborated. Our findings postulate the important role of 
inflammation in inhibitory effect of genipin on HCC, and 
IRE1α as a promising target for disrupting the inflammatory 
environment that favor of HCC development.
RESULTS
Genipin exhibits non-toxic suppression to the in 
vivo growth of HCC
To systematically examine the inhibitory effect of 
genipin on hepatocellular carcinoma, we established the 
orthotopic HCC-implantation mouse model by seeding the 
subcutaneous-grown HCC tumour cubes onto right lobe 
of mice liver, as described in our previous studies [18]. It 
was observed that implanted HCC in mice fed with vehicle 
(saline buffer) continuously grew during the study, while 
mice with oral treatment of genipin (30 mg/kg/2days) 
exhibited slower growth of orthotopic tumour (Figure 
1A). The tumour size at the end of 4-week treatment was 
significantly reduced compared with control group (Figure 
1B) while the body weight of mice was not changed 
(Supplementary Figure S1). There are also no observed 
pathological changes in gastrointestinal, kidney and lung 
sections of genipin-intervened mice (Supplementary 
Figure S2), which indicates that genipin exhibited 
minimal toxicity to the animals. Genipin reduced CD31- 
and Ki67-positive cells within HCC, which postulates 
the suppression of genipin on blood vessel formation 
and proliferative activity of cancer cells (Figure 1C). 
Interestingly, we did not observe any direct cytotoxicity 
of genipin to HCC cells up to 200μM in in vitro culture 
(Figure 1D), nor deceleration of in vitro proliferation of 
HCC cells by genipin treatment (Figure 1E). Our findings 
may indicate an indirect mechanism underlying the 
inhibitory effect of genipin on the in vivo growth of HCC.
Genipin suppresses macrophage infiltration in 
tumour microenvironment of HCC
Many studies also reported the anti-inflammatory 
activities of genipin [16, 19]; but whether genipin drives 
the cross talk between inflammatory cells and cancer 
cells activities remains unidentified. To assess the effect 
of genipin on inflammatory cell infiltration into tumour 
microenvironment, we analysed the expressions of 
myeloid cellular markers on circulating system and liver 
tissues of untreated and genipin-treated mice groups. 
As shown in Figure 2A, the percentage of Ly6C gated 
CCR2hi CX3CR1
lo migratory monocytic populations was 
significantly lowered in liver and tumour tissues of mice 
treated with genipin, whereas there is no changes observed 
in circulating system (result not shown). Because Ly6C 
populations enriched on monocytic myeloid lineages, we 
further detected the expressions of F4/80 macrophage 
marker in tumour tissues of control and genipin-intervened 
groups. Fluorescence immunostaining demonstrated that 
F4/80 stained populations was significantly lowered by 
genipin treatment (Figure 2B). Considering that deletion 
of TAMs may be due to the toxic effect of genipin, we 
first measured if genipin induce macrophage cell death 
as in vivo macrophage population in liver and tumour 
tissues was lowered in mice treated with genipin. As 
observed, up to 200μM, genipin exerted no specific 
cytotoxicity to TAMs (Figure 2C), nor caused apoptosis 
of TAMs (Figure 2D). Furthermore, differentiating F4/80+ 
macrophages using M1 and M2-like representing cell 
surface markers showed no differences between CD86+ 
and CD206+ populations between control and genipin-
treated TAMs (Figure 2E), indicating that genipin-induced 
anti-inflammatory function is independent to TAMs 
polarization. Taken together, our observations reveal 
suppression of TAMs infiltration by genipin without 
significant alteration in cell viability and phenotype.
TAMs as a key mediator in inhibition of in vivo 
HCC growth by genipin
To elaborate the relevance of TAMs in genipin-
mediated anti-tumour activity, we depleted macrophages 
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using liposome clodronate during the course of genipin 
administration (Figure 3A). Depletion of TAMs from 
HCC-bearing mice neutralised the growth inhibition of 
genipin on orthotopic tumour (Figure 3B). There was no 
significant difference between the sizes of tumour with 
or without genipin treatment when TAMs was deleted 
(Figure 3C), indicating that the inhibitory effect of 
genipin on HCC growth involves TAMs. This prompted 
us to further investigate the role of macrophages on HCC 
behaviour upon genipin treatment. We differentiated the 
bone marrow-derived monocytic cells using Hepa 1-6 
tumour supernatant (TSN), as described in our previous 
study [18]. The TSN-derived macrophages (TAMs) were 
cultured with increasing doses of genipin for 48 hours 
before macrophage supernatant (mΦSN) was harvested. 
Co-cultured of Hepa 1-6 cells with genipin pre-treated 
mΦSN reduced Hepa 1-6 proliferation activity as observed 
from the reduced percentage of BrdU positive Hepa 1-6 
cells (Figure 3D). Chemotaxis assay with chemoattractant 
MCP-1 were carried out to measure the migration of 
Figure 1: Genipin suppresses orthotopic growth of HCC without induces toxicity to cancer cells. A. Representative images 
of orthotopic HCC implanted mice. The tumour growth was monitored every week using luciferase live animal imaging. B. Orthotopic 
HCC tumor growth in mice treated with genipin (n=4) was suppressed. The hepatic tumour size was compared between vehicle and 
treatment groups. C. Immunohistochemistry staining of CD31 and Ki67 of hepatic tumour sections between control and genipin group. The 
quantitative analysis of the CD31 and Ki67 expressions was performed by calculating the positive stained cells per 40x field of view (Scale 
bar, 50μm). D. Genipin did not cause cell death to Hepa 1-6 up to 250μM after 48 hours of incubation. The percentage of cell viability of 
Hepa 1-6 cell was determined after treatment with genipin ranging from 0 to 500μM at 24 and 48 hours with MTT assay. E. Genipin at 
40μM had no direct effect on Hepa 1-6 cell proliferation as evidenced from BrdU assay. Details of the experimental protocols are attached 
in Materials & Methods. *p<0.05, **p<0.01, ***p<0.001, compared with untreated group.
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TAMs. TAMs pre-treated with genipin as well as addition 
of genipin along with MCP-1 demonstrated declined 
migratory response compared to non-treated group (Figure 
3E). These findings suggest that the inhibitory effect of 
genipin on in vivo growth of HCC may be correlated with 
TAMs activity in tumour microenvironment.
Genipin reduces TAMs priming in tumour 
microenvironment
CCR2 is primarily expressed on macrophages/
monocytes and the assembly of CCR2 ligands on 
mesenchymal stem cells or tumour cells facilitates 
macrophages recruitment to tumour sites [20]. Blockade 
of CCL2/CCR2 is associated with reduced influx 
of inflammatory monocytes and tumour associated 
macrophages into HCC microenvironment [21]. Initial 
assembly of TAMs induces expressions of a series of 
cytokines, which include but not limited to IL6, TNFα 
and CCL5, further primes the infiltration of monocytes 
and migration of leukocytes [22]. To examine if genipin 
reduce the priming process of TAMs within tumour 
microenvironment, we tested expression of related 
cytokines in TAMs as well as M-CSF-primed BMDMs. 
As the mRNA expression of IL6 is non-detectable, 
we measured its secretion with CBA assay. Genipin 
significantly decreased expressions of inflammatory 
mediators CCR2, TNFα, CCL5, iNOS and IL6 on TAMs 
as well as M-CSF-primed BMDMs (Figure 4A & 4B). On 
the other hand, genipin did not induce marked changes in 
Figure 2: Genipin suppresses TAMs infiltration in tumor microenvironment of HCC. A. The representative FSC-A/SSC-A 
plot diagrams of isolated myeloid populations from mice tumour and liver tissues. Antibodies against CCR2 and CX3CR1 were used to 
stain cell surface marker of migratory monocytic populations. Ly6C was co-stained to identify monocyte population. Percentage of CCR2 
(hi) CX3CR1 (lo) positive cells infiltrating the liver and tumour are shown (n=4 per group). B. Immunohistochemistry staining for F4/80 of 
frozen tumor tissues after genipin treatment. DAPI was used as nuclear counterstain. *p<0.05, compared with vehicle group (n=4) (Scale bar, 
50μm). Genipin did not incur cell death to TAMs up to 200μM as evidenced from C. MTT assay and D. flow cytometry using Annexin V/7-
AAD staining. The detailed protocols for differentiation and culture of TAMs were described in Materials & Methods. E. Genipin-treated 
TAMs showed no difference in CD86/CD206 expression. Antibodies against F4/80 was co-stained for macrophages population and CD86 
and CD206 represent the cell surface markers of M1 and M2 phenotype. *p<0.05, **p<0.01, ***p<0.001, compared with untreated group.
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expressions of anti-inflammatory factors arginase 1, TGFβ 
and IL10 (Supplementary Figure S3). Noting IL6 is the 
primary activator of pro-tumorigenic STAT3 signalling, 
we also measured STAT3 activity in Hepa 1-6 cells co-
cultured with genipin pre-treated mΦSN. We observed 
decreased phosphorylation of STAT3 while addition of IL6 
replenished the effect of genipin on STAT3 inactivation 
(Supplementary Figure S4). This proposed that IL6 may 
be one of the responsible cytokines in inhibitory effect 
of genipin on Hepa 1-6 proliferation. We further isolated 
F4/80+ TAMs from livers of HCC implanted mice by 
FACS sorting. Expressions of CCR2 and TNFα were 
substantially decreased in genipin-intervened group 
(Figure 4C). Consistently, we detected the expressions 
of CCR2 and TNFα on hepatic F4/80+ macrophages were 
markedly lower than that from tumour. These results 
supported the involvement of macrophages in regulating 
the genipin-mediated tumour suppression. The CCR2 
expressions on liver isolated macrophages showed no 
difference in control and genipin-treated mice; while 
TNFα was reduced by genipin treatment (Supplementary 
Figure S5). One of the explanations for this phenomenon 
is the density of isolated liver macrophages may be highly 
consisted of Kupffer cells of liver origin. Besides, the 
reduced expression of related cytokines by genipin was 
diminished by addition of LPS, a robust activator of TLR4 
cascade (Figure 4D). On the other hand, we observed 
genipin decreased XBP-1 mRNA splicing on TAMs in 
dose-dependent manner (Figure 4E), while addition of LPS 
reconstituted spliced XBP-1 (Figure 4F). To determine if 
reduced XBP-1 splicing led to ameliorated endoplasmic 
reticulum (ER) stress, we determine expression of ER 
stress markers CHOP and PERK. As expected, only by 
addition of tunicamycin, the UPR activator induced 
activation of ER stress response. Genipin treatment has 
minimal effect on CHOP and PERK expressions, while 
their upstream regulator, IRE1α was significantly down-
regulated in dose-dependent manner (Figure 4G). Together, 
these findings suggest that genipin could decrease priming 
of TAMs in an ER stress-independent manner.
Figure 3: Inhibition of HCC growth by genipin is TAMs-dependent. A. Schematic diagram of experimental design. B. 
Representative images of orthotopic HCC implanted mice. The tumour growth was monitored every week using luciferase live animal 
imaging. The luciferase signal intensity was plotted by calculating the mean ± SD (n=4). The details of experimental protocols are attached 
in Materials & Methods. C. Representative image of tumour growth of control and genipin-treated mice after macrophage depletion. 
The relative tumour volume was calculated after normalization to the tumour size of control and genipin-treated group in the presence 
of macrophages. D. Genipin reduced HCC proliferation as observed from the 5-Bromo-2’-deoxyuridine incorporation assay. TAMs were 
treated with 40μM genipin for 48 hours and the conditioned media was harvested. Hepa 1-6 cells was cultured in media containing of 
mΦSN (concentration of 1:5) for 24 hours. BrdU assay was performed using BrdU labelling and detection kit I, and the percentage of BrdU 
positive labelled cells were counted randomly in 8 microscopic fields per 40 x field of view. (Scale bar, 50μm). E. Prior and direct treatment 
of genipin on TAMs reduced macrophage migration ability. TAMs were pre-treated with genipin 40μm for 48 hours. Chemotaxis assay was 
performed by seeding the TAMs on culture chamber (8μm) and allow for migration for 16 hours. Soluble MCP-1 (10ng/ml) with or without 
genipin was added into lower insert. The numbers of crystal violet-stained migratory cells were counted randomly in 5 microscopic fields. 
*p<0. 05, **p<0. 01, ***p<0.001, compared with untreated group.
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Inactivation of IRE1α suppresses TAMs priming 
by genipin
Recent study reported that activation IRE1α, 
a conserved sensor of unfolded protein responses is 
responsible on the induction of inflammatory cytokines 
by macrophages [23]. Consistently, we observed the 
genipin treatment reduced IRE1α protein expression 
on F4/80+ macrophages in liver tissue of mice (Figure 
5A), which suggested IRE1α may be the mediator of 
genipin-induced inhibition of inflammatory response. 
To verify the hypothesis, we used RNA interference 
against IRE1α to silent the gene expression on TAMs 
before intervention of genipin. It was accompanied with 
increased IL6 production and normalization of relative 
inflammatory gene expressions between the groups 
with or without genipin (Figure 5B and 5C). As shown 
in Figure 5D, silencing of IRE1α reduced the migratory 
property of macrophage. Culturing of Hepa 1-6 cells with 
IRE1α-silencing TAMs-containing medium also reduced 
the Hepa 1-6 proliferation (Figure 5E). This notion is 
further supported by our observations that the responsible 
inflammatory genes was blocked by IRE1α silencing 
(Figure 5F). Furthermore, we observed the IRE1α highly 
expressed in 7-days differentiated BMDMs with TSN, 
while immature BMDMs at earlier phase expressed much 
lower IRE1α (Supplementary Figure S6). This further 
reveals IRE1α as a crucial factor for the macrophage 
Figure 4: Genipin inhibits activation of TAMs in HCC. A. The mRNAs profile of TAMs and B. M-CSF cultured macrophages 
after treatment with genipin. Total RNA from cells was harvested and expressions of CCR2, TNFα, CCL5 and iNOS were determined by 
RT-qPCR. IL6 cytokine secretion from TAMs cultured supernatant and from M-CSF induced macrophages conditioned media. IL6 content 
was determined with BD CBA kit. The cytokine level was expressed as pg/ml ± SD. C. The mRNA expressions of CCR2 and TNFα on 
FACS-sorted hepatic tumor associated macrophages from control and genipin group. F4/80+ macrophages were sorted from hepatic tumors 
of mice. The mRNA expression was determined by RT-qPCR. Relative fold changes of mRNA levels were calculated after normalization 
to β-actin. D. LPS restored the expressions of CCR2, TNFα, CCL5, iNOS and IL6 in genipin-treated TAMs. The relative fold changes of 
mRNA levels were calculated after normalization to β-actin. E. Reduced XBP1 mRNA splicing was observed in genipin-treated TAMs. 
Total RNA was extracted from TAMs and the levels of XBP1 mRNA (XBP1u: un-spliced, XBP1s: spliced) was determined by semi-
quantitative PCR. β-actin served as loading control. F. LPS replenished the genipin-reduced XBP1 mRNA splicing. The XBP1 mRNA 
expressions of TAMs stimulated with LPS (100ng/ml) after genipin treatment was analysed by semi-qPCR. G. The expressions of IRE1α, 
CHOP and PERK on TAMs after genipin treatment were analysed by immunoblotting. TAMs treated with tunicamycin (10μg/ml) served 
as positive control. *p<0.05, **p<0.01, ***p<0.001, compared with untreated group.
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priming process. Taken together, these results confirmed 
that IRE1α is involved in genipin-correlated inhibitory 
effects on macrophage migration and HCC proliferation.
IRE1α is involved in genipin-correlated 
inactivation of NF-κB via dissociation of IKK 
complex
We observed that genipin induced IκBα 
accumulation and reduced its phosphorylation, down-
regulated IKKα and blocked the translocation of p65 
into nuclear regions of TAMs (Figure 6A & 6B). This 
was accompanied with reduced activation of p65/p50-
specific target genes CXCL1, IL1β and IL12 (Figure 
6C). Addition of TNFα, the NF-κB inducer, replenished 
genipin-induced IκBα accumulation (Figure 6D). 
These results, together with abolishment of decreased 
inflammatory gene expressions induced by genipin 
after intervention of TNFα (Supplementary Figure S7), 
indicate that genipin is a potent NF-κB inhibitor. Further 
investigation of the correlation between IRE1α and NF-
κB signaling showed that RNA interference against 
IRE1α abolished the inhibition of NF-κB by restoring 
the NF-κB related protein expressions to basal levels 
(Figure 6E). IRE1α depletion also blocked the p65 
nuclear translocation (Figure 6F) and replenished the 
reduced expression of p65/p50-transactivated genes in the 
presence of genipin (Supplementary Figure S8). Noting 
that TRAF2, the adaptor molecule of NF-κB, may bridge 
between IRE1α and NF-κB signaling, we performed co-
immunoprecipitation assay with TRAF2 antibody on 
TAMs. It was observed that there is association between 
Figure 5: IRE1α mediates inhibition of TAMs activation by genipin in HCC. A. Treatment of genipin reduced IRE1α 
expression in hepatic tumour. Antibodies against F4/80 (macrophage marker) and IRE1α were used to co-stain the frozen-sectioned hepatic 
tumours. DAPI was used as nuclear counterstain (Scale bar, 50μm). Right panel shows the immunoblotting against IRE1α of FACS-sorted 
TAMs within hepatic tumour of mice with or without genipin treatment. B. The reduced IL6 cytokine levels by genipin was normalized by 
RNA interference against IRE1α. RNA interference was performed as described in Materials & Methods. The relative cytokine content was 
calculated after normalization to the cytokine expression of untreated group. The same also observed in C. mRNAs expressions of genipin-
treated TAMs with IRE1α silencing. The relative mRNAs expression was calculated after normalization to the expression of untreated 
group. D. TAMs with IRE1α silencing had diminished effect on migration property. E. Reduced Hepa 1-6 cell proliferation was observed 
on cells cultured in media containing supernatant of macrophages with IRE1α silencing. F. The inflammatory genes mRNAs expressions 
and IL6 secretion were reduced in TAMs with IRE1α silencing. *p<0. 05, **p<0. 01, ***p<0.001, compared with untreated or mock group.
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TRAF2 and IKKα, IκBα as well as IRE1α (Figure 
6G). While TRAF2 expression had minimal change, 
the reduced IRE1α and IKKα may further reduce the 
association of IRE1α-TRAF2-IKKα by genipin, which 
would lead to inhibition of p65/p50. Surprisingly, we 
couldn’t detect IRE1α during co-immunoprecipitation of 
IKKα, suggested that IKKα has no direct interaction with 
IRE1α. Inactivation of IRE1α dissociated the interaction 
of TRAF2 and IKKα as observed from diminished IKKα 
when IRE1α is deleted, further evidenced that IRE1α as 
an essential mediator in association of IKKα and TRAF2 
(Figure 6H). Taken together, our results postulated that 
inactivation of IRE1α reduced the association of IKKα and 
TRAF2. The activity further led to stabilization of IκBα 
and inhibition of p65 nuclear translocation.
DISCUSSION
Chronic inflammation is one of the important factors 
of carcinogenesis, in which the inflammatory mediators 
such as TNFα, IL-1β and IL-6 secreted by macrophages 
promote tumour growth by deregulating the cell cycle 
checkpoints and cell repair machinery [5]. Although recent 
study classify TAMs into M1 and M2 phenotypes and high 
proportions of pro-inflammatory M1-like macrophages is 
associated with tumour growth regression [24], it is still 
controversial whether inflammation-favourable environment 
is promising therapeutic strategy for cancer therapy. Indeed, 
some studies have reported that the reduced inflammation-
associated macrophages inhibited HCC development, which 
is independent to M1/M2 programming [25]. Moreover, IL6 
Figure 6: Reduced association of IRE1α-TRAF2-IKK may be responsible for genipin-regulated inactivation of NF-κB. 
A. TAMs were treated with 20μM and 40μM genipin for 48 hours. Expressions of IκBα, p-IκBα and IKKα of total extract and p65 in nuclear 
extract were determined by immunoblotting. Lamin B1 served as nuclear loading control. B. Genipin reduced p65 nuclear translocation 
on TAMs. Cells were stained with p65 antibody and counterstained with DAPI, followed with visualization under confocal microscope 
(magnification: 63x). C. Expressions of p65/p50 specific target genes on TAMs after genipin treatment were analyzed by RT-qPCR. D. 
TAMs were treated with genipin in the presence of soluble TNFα (10ng/ml). Expressions of IREα, IκBα, and IKKα were determined. E. 
TAMs with RNA interference against IRE1α were treated with genipin. Expressions of IREα, IκBα, TRAF2 and IKKα were determined. 
F. Silencing of IREα reduced p65 nuclear translocation in TAMs. Expression of p65 in nuclear extract of TAMs was determined. G. The 
interactions of IREα with IκBα, TRAF2 and IKKα were determined by co-immunoprecipitation assay and immunoblotting. TRAF2 was 
immune-precipitated and expressions of interacted proteins were normalized by β-actin as input. H. IKKα protein on wild type and IRE1α 
silencing TAMs was immune-precipitated; the expressions of TRAF2, IKKα and IRE1α (not detected) were determined. *p<0. 05, **p<0. 
01, ***p<0.001, compared with untreated group.
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produced by TAMs promoted cancer stem cell expansion 
and the expression level is proportional to the HCC 
clinical stages [26]. This further indicates that attenuation 
of inflammation independent to macrophage phenotype 
skewing may also be beneficial for HCC treatment. Indeed, 
our study observed reduction of macrophage priming 
by genipin with reduced secretion of pro-inflammatory 
cytokines. This is associated with reduced secondary 
infiltration of inflammatory monocytes and TAMs into 
tumour microenvironment. Besides, we also found that 
treatment of macrophage scavenger, liposome clodronate 
unexpectedly led to reduced growth of HCC, which was 
consistent with the observations in other previous studies 
[27, 28]. This indicates that removal of TAMs from tumour 
microenvironment regardless its phenotype may render 
tumour inhibition. Some “anti-macrophage” treatments are 
currently under investigation. Investigational or approved 
antagonists of TAM-favouring factors, such as CCL2 and 
CCL5, have been proved to be associated with therapeutic 
potential [29]. Our findings on the inhibitory effect of genipin 
on TAMs priming and infiltration, postulated the evidence of 
inflammation suppressor in anti-cancer treatment.
Accumulating studies have demonstrated the role 
of IRE1α in modulating the pathogenesis of inflammation 
associated diseases such as inflammatory arthritis, diabetes 
and dyslipidaemia [23, 30, 31]. Most of the time, activated 
IRE1α induces unconventional splicing of 26-nucleotide 
stretch from the mRNA encoding X-box-binding protein 
1 (XBP-1), resulted in encoding of spliced XBP-1, that 
translocate to nucleus for initiation of unfolded protein 
response (UPR) related genes transcription [32]. In addition 
to the conventional ER signal sensing, recent studies have 
extended the role of IRE1α-XBP-1 axis to modulation 
of metabolic homeostasis and immune response [33, 
34]. Previous study showed that the engagement of toll 
like receptors to IRE1α induced XBP-1 splicing on 
macrophages leading to enhanced production of IL6 and 
TNFα independent to ER stress [33]. In consistent with 
our study, we also observed increased XBP-1 processing 
on TSN induced macrophages and addition of genipin 
blocked XBP-1 cleavage without incurring any stress 
response on macrophages. Although we did not perform 
XBP1 deletion, our findings evidenced that IRE1α-XBP1 
axis is likely involved in genipin-repressed inflammatory 
response. First, genipin down-regulated the expressions 
of IL6 and TNFα, the mature XBP1 trans-activated 
genes. Second, intervention of LPS, the TLR4 agonist 
reconstituted the spliced XBP1 and increased the levels of 
IL6 and TNFα, rather than normalize them.
IRE1α also mediates inflammation through 
engagement with several downstream effectors [31, 35]. 
Previous study suggested that XBP1 deletion may not 
sufficient in blocking the broad spectrum of inflammatory 
genes expression [23]; and consistently, our study 
demonstrated that IRE1α deletion normalized a group of 
inflammatory genes apart from XBP-1 regulated IL6 and 
TNFα. The cytoplasmic kinase domain of activated IRE1α 
interacts with JNK and IκB kinase (IKK) via adaptor 
protein TRAF2, and the binding is likely determined by 
the degree of IRE1α oligomerization [36]. In our study, we 
did not observed reduction of TRAF2, the adaptor protein 
of IRE1α. The inhibitory effect of IRE1α suppression by 
genipin on downstream NF-κB machinery may be therefore 
due to dissociation of IRE1α from TRAF2 binding. 
Indeed, previous study demonstrated that IRE1α forms 
complex with IKK through TRAF2 and the activity further 
leads to phosphorylation of IκBα and NF-κB activation 
[37], indicated that IRE1α is the essential mediator for 
interaction between IKK and TRAF2. Reduction of IRE1α 
by genipin therefore abrogated the association of IKK and 
TRAF2, which as a result stabilized IκBα and blocked the 
nuclear translocation of p65/p50 (Figure 7).
Figure 7: Schematic diagram of the mechanisms underlying inhibition of TAMs by genipin.
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In conclusion, our results demonstrated that the 
tumour suppressive effect of genipin was mediated by 
TAMs. Genipin potently inhibited in vivo orthotopic 
growth of HCC and significantly reduced infiltration 
of inflammatory monocytes and TAMs in HCC 
microenvironment. Genipin suppressed migration of 
TAMs and expression of macrophage priming-related 
cytokines. Inhibition of TAMs priming by genipin was 
correlated with its effect in specifically deletion of IRE1α 
in TAMs. Regulation of genipin on TAMs involved 
inactivation of XBP-1 splicing and NF-κB machinery. 
The study suggests genipin, aiming at IRE1α inactivation 
may represent a promising immunomodulatory therapeutic 
candidate for hepatocellular carcinoma.
MATERIALS AND METHODS
Animal studies
The detailed animal model establishment has been 
reported in our previous study [18]. Luciferase-tagged 
HCC cells-constituting tumor were cut into 1mm3 before 
implanted into the left lobe of mice liver. After one week 
of laparotomy, the growth of liver tumor was examined 
via luciferase imaging analysis. All tumor-presenting 
mice were then orally given genipin (30 mg/kg/2days) 
or equal volume of PBS (n=4) for 5 weeks. Liver tumor 
growth was monitored weekly. Macrophage depletion 
was performed as indicated in Figure 3A. Briefly, mice 
in macrophage removal groups were intraperitoneally 
administrated with clodronate liposome (0.1ml/10g, 
ClodronateLiposomes.com, Netherland) every 4 days 
along with genipin intervention. Animal experimental 
protocols were approved by the Committee on the Use of 
Live Animals in Teaching and Research (CULATR) of The 
University of Hong Kong, Hong Kong.
Fluorescence activated cell sorting (FACS)
Liver and tumor tissues were minced and harvested 
with collagenase solution at 37°C for 30 minutes. The 
pellets were re-suspended in RPMI 1640 and mononuclear 
cells were separated according to Percoll density gradient 
centrifugation procedure. Cells were washed with PBS and 
stained with anti-mouse CCR2, CX3CR1, Ly6C, F4/80, 
CD86 and CD206 antibody for 15 minutes. Corresponding 
isotypes antibodies were used as controls. The FACS 
analysis was performed on FACS Canto II cytometer 
(BD) and cell sorting on FACS Aria I cytometer (BD). 
Data were analyzed with FlowJo software.
Immunohistochemistry staining
Tumor tissues were fixed with 4% paraformaldehyde 
and then 30% sucrose solution. Frozen sections were cut 
and incubated with CD31, Ki67 and F4/80 antibodies. The 
stained slides were visualized under fluorescent microscope.
Isolation of bone marrow derived mononuclear 
cells and macrophage migration
Bone marrow derived mononuclear cells (BMDMs) 
were harvested from femurs and tibias of 6- to 8-week-
old C57BL/6 mice and cultured with complete RPMI-
1640 (supplemented with 10% Fetal Bovine Serum and 
1% Penn/Strep). The differentiation of mononuclear 
cells to macrophages was performed either by culturing 
the isolated BMDMs with murine M-CSF (10ng/mL) 
or 30% tumor cell culture supernatant for 7 days. The 
detailed procedures are described in our previous study 
[18]. Migration assay was performed through seeding the 
macrophages on receiving insert (8μm, Corning, USA) 
and allowed to migrate for 16 hours. The chambers were 
then removed and the cells under chamber were fixed 
in 4% paraformaldehyde. The fixed cells stained with 
crystal violet for 2 hours before visualized by inverted 
microscopy.
Co-culture of HCC cells with macrophage 
supernatant
The macrophage-conditioned medium was 
harvested after the macrophages incubated with genipin 
for 48 hours. The Hepa 1-6 cells were cultured in 20% 
macrophage supernatant (1:5 final dilution) and incubated 
for 24 hours. Cell proliferation activity was measured by 
5-Bromo-2’-deoxyuridine labelling and detection kit I 
(Roche), according to manufacturer’s instructions. The 
image was captured using fluorescent microscopy.
Western blotting
Total protein was extracted from HCC and 
macrophage cells via RIPA lysis buffer supplemented with 
cocktail proteinase inhibitor and phosphatase inhibitor 
(1mM Na3VO4 and 1mM NaF). Nuclear extraction was 
performed using nuclear extraction buffer (ThermoFisher). 
The protein lysates were separated on SDS-PAGE gel and 
blotted onto polyvinylidene difluoride membranes. The 
membrane was incubated with IRE1α, CHOP, PERK, 
TRAF2, IKKα, IκBα, and β-actin. The blots were labeled 
with HRP–labelled secondary antibody before subjected to 
chemiluminescence analysis.
Quantitative real time PCR
Total RNA was isolated with TRIzol reagent 
(Invitrogen) and cDNA was synthesized with PrimeScript 
RT Reagent kit (TaKaRa), according to manufacturer’s 
instructions. Real time PCR was performed using SYBR 
Green Master mix (TaKaRa) and 1μM primers using Light 
Cycler 480 PCR system (Roche, USA). The murine β-actin 
serves as endogenous control and primers sequences are 
listed in Supplementary Table S1.
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RNA interference
The macrophage cells were incubated with RPMI 
1640 without antibiotics that pre-mixed with 10μM of 
Lipofectamine RNAiMAX (Invitrogen) and 1nmol of 
siRNA (FlexiTube, Qiagen), according to manufacturer 
instructions. The transfection efficiency was assessed by 
immunoblotting assay.
Immunofluorescence staining
Prior to immunofluorescence staining, macrophages 
cells were grown on glass coverslip and cultured with 
or without genipin. After fixing the cells with 4% 
paraformaldehyde, the cells were stained with p65 
antibody and counterstained with DAPI. Specimen 
was mounted and examined by fluorescence confocal 
microscopy (Carl Zeiss LSM780).
Co-immunoprecipitation assay
The assay was performed using protein G magnetic 
beads (Pureproteome Millipore), based on manufacturer 
instructions. The target protein was precipitated with 
antibody that pre-bound with magnetic beads, followed 
with elution with PBS in 0.1% Tween 20. The protein 
lysates were separated on SDS-PAGE and visualized using 
chemiluminescence system.
Statistical analysis
Data were analyzed as mean value ± SD and 
Student’s T-test or two-way ANOVA was used to assess 
the result significance. A p value < 0.05 was deemed as 
statistically significant.
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